中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

42 records (took 0.01 seconds)

    Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
    2.
    发明授权
    Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof 有权

    公开(公告)号：US11633501B2

    公开(公告)日：2023-04-25

    申请号：US16992453

    申请日：2020-08-13

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： John Rudge ,  Frank Delfino ,  Lauric Haber ,  Eric Smith ,  Jessica R. Kirshner ,  Alison Crawford ,  Thomas Nittoli

    IPC: A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C07K16/40 ,  C07K16/46 ,  A61K39/00

    Abstract: The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.

    Multispecific antigen-binding molecules and uses thereof
    4.
    发明授权
    Multispecific antigen-binding molecules and uses thereof 有权

    公开(公告)号：US11129903B2

    公开(公告)日：2021-09-28

    申请号：US15202822

    申请日：2016-07-06

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： Julian Andreev ,  Nithya Thambi ,  Frank Delfino ,  Joel Martin ,  Gavin Thurston ,  Katherine Cygnar ,  Nicholas Papadopoulos

    IPC: A61K47/68 ,  C07K16/22 ,  C07K16/28 ,  C07K1/32 ,  C07K16/12 ,  C07K16/18 ,  C07K14/47 ,  C07K16/30 ,  A61P35/00 ,  C07K16/46 ,  A61K39/00 ,  C12N9/64 ,  C07K16/32

    Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.

    Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
    5.
    发明授权
    Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof 有权

    公开(公告)号：US10772972B2

    公开(公告)日：2020-09-15

    申请号：US15713569

    申请日：2017-09-22

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： John Rudge ,  Frank Delfino ,  Lauric Haber ,  Eric Smith ,  Jessica R. Kirshner ,  Alison Crawford ,  Thomas Nittoli

    IPC: A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C07K16/40 ,  C07K16/46 ,  A61K39/00

    Abstract: The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human STEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.

    Bispecific Anti-BCMA x Anti-CD3 Antibodies and Uses Thereof
    10.
    发明申请
    Bispecific Anti-BCMA x Anti-CD3 Antibodies and Uses Thereof 有权

    公开(公告)号：US20220306758A1

    公开(公告)日：2022-09-29

    申请号：US17828847

    申请日：2022-05-31

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Eric Smith ,  Kara Olson ,  Frank Delfino ,  David DiLillo ,  Jessica Kirshner ,  Olga Sineshchekova ,  Qian Zhang

    IPC: C07K16/28 ,  C07K16/46

    Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma.

Patent Agency Ranking